Albemarle Narrows Losses Amid Lithium Price Headwinds

TL;DR

**ALB is still losing money, but the bleeding has slowed significantly, making it a speculative buy for a lithium rebound.**

AI Summary

Albemarle Corporation reported a significant net loss attributable to common shareholders of $202.38 million for the three months ended September 30, 2025, a substantial improvement from the $1.11 billion loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss attributable to common shareholders was $221.51 million, compared to a $1.35 billion loss in 2024. Net sales decreased to $1.31 billion for the three-month period in 2025 from $1.35 billion in 2024, and to $3.71 billion for the nine-month period in 2025 from $4.15 billion in 2024. The company incurred goodwill impairment charges of $181.07 million in the third quarter of 2025, which were not present in 2024. Restructuring charges and asset write-offs significantly decreased to $2.28 million in Q3 2025 from $828.15 million in Q3 2024. Cash and cash equivalents increased to $1.93 billion as of September 30, 2025, from $1.19 billion at December 31, 2024, driven by $893.78 million in net cash provided by operating activities for the nine-month period. The decline in lithium market pricing led to inventory valuation adjustments of $11.1 million at September 30, 2025, down from $104.0 million at December 31, 2024.

Why It Matters

Albemarle's reduced net loss, despite lower sales and a new goodwill impairment charge, signals a potential stabilization in its core lithium business, which is crucial for the electric vehicle supply chain. For investors, the significant decrease in restructuring charges from $828.15 million to $2.28 million year-over-year suggests that the major cost-cutting initiatives may be winding down, potentially improving future profitability. The competitive landscape in the lithium market remains intense, and Albemarle's ability to manage inventory valuation adjustments, which decreased from $104.0 million to $11.1 million, indicates a more controlled response to market price fluctuations. This performance impacts employees through potential job stability and customers through more predictable supply, while the broader market watches for signs of recovery in the critical minerals sector.

Risk Assessment

Risk Level: medium — The company reported a net loss attributable to common shareholders of $202.38 million for the three months ended September 30, 2025, and $221.51 million for the nine months ended September 30, 2025, indicating ongoing unprofitability. Additionally, a goodwill impairment charge of $181.07 million in Q3 2025 highlights potential overvaluation of assets and future earnings uncertainty, contributing to a medium risk profile.

Analyst Insight

Investors should closely monitor lithium market prices and Albemarle's future inventory valuation adjustments, as these directly impact profitability. Consider this a speculative long-term play on the EV market's recovery, but be aware of continued losses and asset impairment risks.

Financial Highlights

revenue

$1.31B

net Income

-$160.69M

eps

-$1.72

gross Margin

9.00%

cash Position

$1.93B

revenue Growth

-3.45%

Revenue Breakdown

Key Numbers

• $202.38M — Net Loss Attributable to Common Shareholders (Q3 2025) (Significantly improved from $1.11B loss in Q3 2024)
• $1.31B — Net Sales (Q3 2025) (Decreased from $1.35B in Q3 2024)
• $181.07M — Goodwill Impairment Charges (Q3 2025) (New charge impacting profitability)
• $2.28M — Restructuring Charges (Q3 2025) (Substantially down from $828.15M in Q3 2024)
• $1.93B — Cash and Cash Equivalents (Sept 30, 2025) (Increased from $1.19B at Dec 31, 2024)
• $893.78M — Net Cash Provided by Operating Activities (Nine Months 2025) (Strong cash generation from operations)
• $11.1M — Inventory Valuation Adjustments (Sept 30, 2025) (Reduced from $104.0M at Dec 31, 2024 due to lithium pricing)
• $1.72 — Basic Loss Per Share (Q3 2025) (Improved from $9.45 in Q3 2024)

Key Players & Entities

• ALBEMARLE CORPORATION (company) — registrant
• SEC (regulator) — U.S. Securities and Exchange Commission
• $202.38 million (dollar_amount) — Net loss attributable to Albemarle Corporation common shareholders for Q3 2025
• $1.11 billion (dollar_amount) — Net loss attributable to Albemarle Corporation common shareholders for Q3 2024
• $221.51 million (dollar_amount) — Net loss attributable to Albemarle Corporation common shareholders for nine months ended September 30, 2025
• $1.35 billion (dollar_amount) — Net loss attributable to Albemarle Corporation common shareholders for nine months ended September 30, 2024
• $1.31 billion (dollar_amount) — Net sales for Q3 2025
• $181.07 million (dollar_amount) — Goodwill impairment charges for Q3 2025
• $828.15 million (dollar_amount) — Restructuring charges and asset write-offs for Q3 2024
• $1.93 billion (dollar_amount) — Cash and cash equivalents as of September 30, 2025

FAQ

Risk Factors

• Lithium Market Price Volatility [high — market]: The company's profitability is significantly impacted by fluctuations in lithium market pricing. Lower pricing in 2025 led to inventory valuation adjustments of $11.1 million, a decrease from $104.0 million at the end of 2024, indicating ongoing price sensitivity.
• Goodwill Impairment [medium — operational]: Albemarle incurred goodwill impairment charges of $181.07 million in Q3 2025. This indicates that the carrying value of goodwill on the balance sheet is no longer supported by the expected future cash flows from the acquired assets, suggesting potential overpayment or underperformance of past acquisitions.
• Restructuring and Asset Write-offs [medium — operational]: While significantly reduced to $2.28 million in Q3 2025 from $828.15 million in Q3 2024, substantial restructuring charges and asset write-offs in the prior year highlight past operational challenges or strategic realignments that impacted financial performance.
• Environmental and Permitting Regulations [medium — regulatory]: As a producer of lithium and other specialty chemicals, Albemarle is subject to stringent environmental regulations and permitting requirements. Changes in these regulations or delays in obtaining permits could impact production capacity and operational costs.
• Debt and Financing Expenses [medium — financial]: The company reported $50.96 million in interest and financing expenses for Q3 2025. Managing its debt obligations and financing costs is crucial, especially in a period of reduced profitability.

Industry Context

Albemarle operates in the highly competitive lithium and bromine markets, essential components for electric vehicle batteries and various industrial applications. The industry is characterized by significant capital investment requirements, cyclical pricing, and increasing demand driven by the global energy transition. Competitors include other major lithium producers and emerging players, with ongoing consolidation and strategic partnerships shaping the landscape.

Regulatory Implications

Albemarle faces significant regulatory scrutiny related to environmental impact, particularly concerning mining and chemical processing. Compliance with evolving environmental standards, obtaining and maintaining permits for operations, and managing potential liabilities associated with chemical production are critical areas of focus. Changes in trade policies and tariffs could also impact international sales and sourcing.

What Investors Should Do

1. Monitor lithium pricing trends closely.
2. Assess the impact of goodwill impairment charges.
3. Analyze the reduction in restructuring charges.
4. Evaluate the strength of operating cash flow.

Glossary

Goodwill impairment charges

An accounting charge taken when the carrying value of goodwill on a company's balance sheet is deemed to be irrecoverable, usually because the acquired business is not performing as expected. (Albemarle recorded $181.07 million in goodwill impairment in Q3 2025, directly reducing net income and indicating a potential overvaluation of past acquisitions.)

Restructuring charges and asset write-offs

Costs incurred when a company reorganizes its operations, which can include severance pay, lease termination costs, and the disposal of underperforming assets. (A significant decrease in these charges from $828.15 million in Q3 2024 to $2.28 million in Q3 2025 suggests a reduction in ongoing or past significant operational overhauls.)

Equity in net income of unconsolidated investments

A company's share of the profits or losses from investments in companies where it does not have control (e.g., joint ventures), accounted for using the equity method. (Albemarle's equity in net income from unconsolidated investments was $60.64 million in Q3 2025, contributing positively to the overall net income despite operational losses.)

Inventory valuation adjustments

Changes made to the recorded value of inventory to reflect current market conditions, such as declines in selling prices or obsolescence. (The company made adjustments of $11.1 million in Q3 2025 due to lithium pricing, reflecting the impact of market dynamics on inventory value.)

Mandatory convertible preferred stock dividends

Dividends paid on preferred stock that is required to convert into a specified number of common shares of the issuing company after a certain period. (These dividends of $41.69 million in Q3 2025 reduce the net income available to common shareholders.)

Year-Over-Year Comparison

Albemarle Corporation's Q3 2025 results show a mixed picture compared to Q3 2024. Net sales saw a slight decrease of 3.45% to $1.31 billion, reflecting challenging market conditions. However, the net loss attributable to common shareholders significantly improved, narrowing from $1.11 billion to $202.38 million. This improvement was driven by a substantial reduction in restructuring charges and asset write-offs, which fell from $828.15 million to $2.28 million. Conversely, the company incurred new goodwill impairment charges of $181.07 million in Q3 2025, which were absent in the prior year. Cash and cash equivalents saw a healthy increase, bolstering the company's liquidity.

Filing Documents

• alb-20250930.htm (10-Q) — 2235KB
• exhibit1010930202510q.htm (EX-10.1) — 138KB
• exhibit1020930202510q.htm (EX-10.2) — 201KB
• exhibit1030930202510q.htm (EX-10.3) — 150KB
• exhibit1040930202510q.htm (EX-10.4) — 91KB
• exhibit1050930202510q.htm (EX-10.5) — 66KB
• exhibit3110930202510q.htm (EX-31.1) — 10KB
• exhibit3120930202510q.htm (EX-31.2) — 10KB
• exhibit3210930202510q.htm (EX-32.1) — 5KB
• exhibit3220930202510q.htm (EX-32.2) — 5KB
• 0000915913-25-000162.txt ( ) — 12361KB
• alb-20250930.xsd (EX-101.SCH) — 65KB
• alb-20250930_cal.xml (EX-101.CAL) — 100KB
• alb-20250930_def.xml (EX-101.DEF) — 349KB
• alb-20250930_lab.xml (EX-101.LAB) — 766KB
• alb-20250930_pre.xml (EX-101.PRE) — 589KB
• alb-20250930_htm.xml (XML) — 2227KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) Consolidated Statements of Loss - Three and Nine Months Ended September 30, 2025 and 2024 4 Consolidated Statements of Comprehensive (Loss) Income - Three and Nine Months Ended September 30, 2025 and 2024 5 Consolidated Balance Sheets - September 30, 2025 and December 31, 2024 6 Consolidated Statements of Changes in Equity - Three and Nine Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2025 and 2024 9 Notes to the Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 56 Item 4.

Controls and Procedures

Controls and Procedures 57 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 57 Item 1A.

Risk Factors

Risk Factors 57 Item 5. Other Information 57 Item 6. Exhibits 57

SIGNATURES

SIGNATURES 59 EXHIBITS 3 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited). ALBEMARLE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF LOSS (In Thousands, Except Per Share Amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net sales $ 1,307,829 $ 1,354,692 $ 3,714,702 $ 4,145,813 Cost of goods sold (a) 1,190,219 1,458,726 3,243,917 4,221,487 Gross profit (loss) 117,610 ( 104,034 ) 470,785 ( 75,674 ) Selling, general and administrative expenses 138,577 154,253 394,536 482,052 Goodwill impairment charges 181,070 — 181,070 — Restructuring charges and asset write-offs 2,275 828,146 5,660 1,156,522 Research and development expenses 12,674 22,397 39,217 66,699 Operating loss ( 216,986 ) ( 1,108,830 ) ( 149,698 ) ( 1,780,947 ) Interest and financing expenses ( 50,959 ) ( 47,760 ) ( 149,875 ) ( 120,916 ) Other income (expenses), net 28,799 ( 22,256 ) 32,490 61,311 Loss before income taxes and equity in net income of unconsolidated investments ( 239,146 ) ( 1,178,846 ) ( 267,083 ) ( 1,840,552 ) Income tax (benefit) expense ( 30,565 ) 110,853 ( 449 ) 76,472 Loss before equity in net income of unconsolidated investments ( 208,581 ) ( 1,289,699 ) ( 266,634 ) ( 1,917,024 ) Equity in net income of unconsolidated investments (net of tax) 60,640 229,058 203,184 696,436 Net loss ( 147,941 ) ( 1,060,641 ) ( 63,450 ) ( 1,220,588 ) Net income attributable to noncontrolling interests ( 12,753 ) ( 8,351 ) ( 32,999 ) ( 34,154 ) Net loss attributable to Albemarle Corporation ( 160,694 ) ( 1,068,992 ) ( 96,449 ) ( 1,254,742 ) Mandatory convertible preferred stock dividends ( 41,688 ) ( 41,687 ) ( 125,063 ) ( 94,959 ) Net loss attributable to Albemarle Corporation common shareholders $ ( 202,382 ) $ ( 1,110,679 ) $ ( 221,512 ) $ ( 1,349,701 ) Basic loss per share attributable to common shareholders $ ( 1.72 ) $ ( 9.45 ) $ ( 1.88 ) $ ( 11.49 ) Diluted loss per share attributable to common shareholders $ ( 1.72 ) $ ( 9.45 ) $ ( 1.88 )

View Full Filing

View this 10-Q filing on SEC EDGAR